Etravirine

ARV U.S. Brand Name

Intelence

ARV Abbreviation(s)

ETR

U.S. FDA Label

Etravirine Labeling (Package Insert)

ARV Class

Nonnucleoside reverse transcriptase inhibitors

First U.S. Approval

January 18, 2008

U.S. Manufacturer

Janssen

Formulations

Strength	Formulation	Image	Description	Boosted
25 mg	Tablet	X	oval white tablet with TMC125 imprint	No
150 mg	Tablet	X	white oval tablet with divit in the center	No
200 mg	Tablet	X	white oval pill with T200 imprint	No

Generic Available?

Assistance Programs

Janssen Care Path

Displaying 1 - 79 of 79

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Lenacapavir Etravirine	Red: Avoid combination	Do not coadminister: potentially reduced levels of lenacapavir	Potential loss of antiviral efficacy				Use alternative agents.
Ritonavir ETR 1034	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of etravirine				Etravirine AUC decreased 46%; Cmax decreased 32%	For ritonavir boosting - refer to individual protease inhibitors for specific recommendation
Darunavir ETR 917	Green: Administer standard doses	Administer standard doses			200 mg twice daily
Darunavir ETR 908	Green: Administer standard doses	Administer standard doses		Not reported	100 mg BID	Cmax decrease 32%, AUC decrease 37%, Cmin decrease 49%
Atazanavir ETR 841	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir and increased levels of etravirine	Potential increased etravirine effects, decreased atazanavir effects	Atazanavir AUC decreased 17%, Cmin decreased 47%		Etravirine AUC increased 50%, Cmax increased 47%, Cmin increased 58%	Use alternative agents
Tenofovir disoproxil fumarate ETR 733	Green: Administer standard doses	Administer standard doses		Cmax increase 15%, AUC increase 15%, Cmin increase 19%	200 mg BID	Cmax decrease 19%, AUC decrease 19%, Cmin decrease 18%
Nevirapine ETR 617	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Decreased etravirine and nevirapine effects	levels): increased 15-30%		Etravirine AUC decreased 55%	Use alternative agents
Etravirine ATV 574			Potential for increased etravirine effects	Etravirine AUC increased 30%; Cmax increased 30%; Cmin decreased 26%	300 mg daily with 100 mg ritonavir daily	Atazanavir AUC decreased 14%; Cmin decreased 38%	When using atazanavir 300 mg plus ritonavir 100 mg once daily use etravirine standard dose.
Etravirine Verapamil 573	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased verampil efficacy				If coadministring, titrate verapamil based on clinical response
Etravirine Diltiazem 572	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased dilitazem efficacy				If coadministring, titrate dilitazem based on clinical response
Etravirine Warfarin 571	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased Warfarin concentration				If coadministring, monitor INR
Etravirine Trazodone 570	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiential decreaed Trazodone effects				If coadministring, monitor for theraptutic effectiveness of Trazodone
Etravirine Sertraline 569	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiential decreaed Sertaline effects				If coadministring, monitor for theraptutic effectiveness of Sertaline
Etravirine Zonisamide 568	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Tiagabine 567	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Lacosamide 566	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Ethosuximide 565	Orange: Minimal data to guide interaction	minimal data to guide interaction: weigh risks and benefits of using this combination	Potiental decreased anticonvulsant effects				if co-administring, monitor for seizure control
Etravirine Lumefantrine 564	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased antimalarial effects	No significant change	artemether / Lumefantrine 80 / 480 mg	Lumefantrine AUC decreased 13%	If coadministering, monitor for anti-malarial efficacy.
Etravirine Itraconazole 563	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased itraconazole effects	Not studied (may increase etravirine levels)		Not studied (may decrease itraconazole levels)	If coadministering, dose adjustment not established. Monitor itraconazole levels and etravirine toxicity.
Etravirine Artemether / Lumefantrine 562	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased antimalarial effects	No significant change	artemether / lumefantrine 80 / 480 mg	Artemether AUC decreased 38%; Lumefantrine AUC decreased 13%	Use with caution; avoid if possible
Etravirine Clarithromycin 561	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased etravirine effects; decreased clarithromycin effects	Etravirine AUC increased 42%; Cmax increased 46%; Cmin increased 46%	500 mg BID	Clarithromycin AUC decreased 37%; Cmax decreased 34%; Cmin decreased 53%; 14-hydroxyclarithromycin AUC increased 21%; Cmax increased 33%	Use alternative macrolide (consider use of azithromycin) for MAC
Etravirine Bosentan 560	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased etravirine effects; potential decreased bosentran effects				If coadministring, monitor bosentran efficacy and virologic response
Etravirine Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 559	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potentially decreased or increased elvitegravir, cobicistat and / or etravirine effects	No significant change	Elvitegravir 150 mg daily	No significant change	Avoid combination and use alternative agents
Etravirine Clopidogrel 558	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased clopidogrel effects				Avoid combination and use alternative agents
Etravirine Tamsulosin 557	Orange: Minimal data to guide interaction	Adjust dosing to avoid decreased levels of tamsulosin	Decreased tamsulosin effects				If coadministring, monitor for theraptutic effectiveness of tamsulosin after 2-4 weeks. Increase dose to 0.8mg daily for patients who fail to respond to 0.4 mg dose.
Etravirine Phenytoin 556	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and phenytoin	Potential decreased etravirine effects; potential decreased anticonvulsants effects
Etravirine CBZ 555	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and carbamazepine	Potential decreased etravirine effects; potential decreased anticonvulsants effects
Etravirine Phenobarbital 554	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and phenobarbital	Potential decreased etravirine effects; potential decreased anticonvulsants effects				Avoid combination and use alternative agents
Etravirine NVP 553	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine					Avoid combination: :combining two NNRTIs has not been shown beneficial use alternate agents
Etravirine EFV 552	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine					Avoid combination: combining two NNRTIs has not been shown beneficial; use alternate agents
Etravirine SOF/VEL 551	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir and voxilaprevir	Potential loss of anti-HCV efficacy	Not studied		Not studied (may decrease velpatasvir and voxilaprevirlevels)	Contraindicated. Use alternative agents.
Etravirine SOF/VEL 550	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir	Potential loss of anti-HCV efficacy	Not studied		Not studied (may decrease velpatasvir and sofosbuvir levels)	Contraindicated. Use alternative agents.
Etravirine Pimavanserin 549	Red: Avoid combination	Do not coadminister: potientially reduced levels of pimavanserin	Potential decreased pimavanserin effects				Contraindicated. Use alternative agents.
Etravirine Cariprazine 548	Red: Avoid combination	Do not coadminister: potientially reduced levels of cariprazine	Potential decreased cariprazine effects				Contraindicated. Use alternative agents.
Etravirine Lumateperone 547	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Decreased Lumateperon levels				Avoid combination and use alternative agents
Etravirine G/P 546	Red: Avoid combination	Do not coadminister: Potential for reduced levels of glecaprevir / Pibrentasvir	Potentially decreased glecaprevir / pibrentasvir levels expected			Not studied (may decrease grazprevir levels)	Avoid combination. Use alternative agents
Etravirine RIF 545	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine	Significant decrease in etravirine efficacy
Etravirine RPT 544	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etraviorine	Potential decreased etravirine effects
Etravirine St. John's Wort (Hypericum perforatum) 543	Red: Avoid combination	Do not coadminister: Potential for reduced levels of ETR	loss of virologic response	Not studied		Not studied	Contraindicated. Use alternative agents.
Etravirine EBR/GZR 542	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Potentially decreased elbasvir, grazoprevir levels expected	Not studied		Not studied (may decrease grazprevir levels)	Avoid combination. Use alternative agents
Etravirine DTG 541	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dolutegravir	Potentially reduced dolutegravir effectiveness		50 mg daily	Dolutegravir AUC decreased 71%; Cmin decreased 88%	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. If one of these boosted PIs is present and known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
Etravirine Bedaquiline 540	Red: Avoid combination	Do not coadminister: Potential for reduced levels of bedaquiline	potentially reduced levels of bedaquiline
Etravirine ATV/c 539	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy	Not studied		Not studied; Potential decreased atazanavir and cobicistat levels)	Use alternative agents
Etravirine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 538	Red: Avoid combination	Do not coadminister: Potential for reduced levels of anti-HCV agents	Potential decrease in anti-HCV efficacy	Not studied		Not studied (may decrease paritaprevir levels)	Use alternative agents
Etravirine DTG 537	Red: Avoid combination	Administer standard doses			50 mg daily	Dolutegravir AUC increased 11%; Cmin increased 28%	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. When using this combo and there is known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
Etravirine DTG 536	Red: Avoid combination	Administer standard doses	Potentially reduced dolutegravir effectiveness		50 mg daily	Dolutegravir AUC decreased 25%; Cmin decreased 37%	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. When using this combo and there is known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
Etravirine Omeprazole 535	Green: Administer standard doses	Administer standard doses		Etravirine AUC increased 41%	40 mg daily x 11 days
Etravirine Ranitidine 534	Green: Administer standard doses	Administer standard doses		No significant change	150 mg BID x 11 days
Etravirine Methadone 533	Green: Administer standard doses	Administer standard doses			60-130 mg daily	R-methadone: no significant effect; S-methadone: no significant effect
Etravirine RAL 532	Green: Administer standard doses	Administer standard doses		Etravirine Cmin increased 17%	400 mg BID	Raltegravir Cmin decreased 34%
Etravirine Paroxetine 531	Green: Administer standard doses	Administer standard doses		No significant change	20 mg daily	No significant change
Etravirine Ethinyl estradiol / Norethindrone acetate 530	Green: Administer standard doses	Administer standard doses			0.035 mg EE / 1 mg NE daily	Ethinyl estradiol AUC increased 22%; Cmax increased 33%; Norethindrone Cmin decreased 22%
Etravirine DRV 529	Green: Administer standard doses	Administer standard doses		Etravirine AUC increased 80%; Cmax increased 81%; Cmin increased 67% (compared to etravirine 100 mg BID)		Darunavir AUC increased 15%
Etravirine DRV 528	Green: Administer standard doses	Administer standard doses		Etravirine AUC decreased 37%; Cmax decreased 32%; Cmin decreased 49%	600 mg BID with 100 mg ritonavir BID	No significant change
Etravirine Voriconazole 527	Green: Administer standard doses	Administer standard doses	Potential for increased etravirine effects	Etravirine AUC increased 36%; Cmin increased 52%; Cmax increased 26%	200 mg BID	Voriconazole Cmin increased 23%
Etravirine Saxagliptin 526	Green: Administer standard doses	Administer standard doses	Possible decrease in antihyperglycemic effects				Monitor glycemic control
Etravirine Linagliptin 525	Green: Administer standard doses	Administer standard doses	Possible decrease in antihyperglycemic effects				Monitor glycemic control
Etravirine Midazolam 524	Green: Administer standard doses	Administer standard doses	decreased levels of midazolam			Midozolam AUC decreased 31%; active metabolite Cmax increased 57%	Monitor for theraputive effectiveness of midazolam
Etravirine Sildenafil 523	Green: Administer standard doses	Administer standard doses	Decreased sildenafil effects		50 mg x 1	Sildenafil AUC decreased 57%; Cmax decreased 45%	Monitor for sildenafil efficacy and titrate to effect
Etravirine Fluconazole 522	Green: Administer standard doses	Administer standard doses	Increased etravirine effects	Etravirine AUC increased 86%; Cmax increased 75%; Cmin increased 109%	200 mg QAM	No significant change	Monitor for fluconazole associated toxicities
Etravirine Posaconazole 521	Green: Administer standard doses	Administer standard doses		Not studied (may increase etravirine levels)		Not studied	Monitor for etravirine related toxicities
Etravirine RFB 520	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Decreased rifabutin effects	Etravirine AUC decreased 37%; Cmax decreased 37%; Cmin decreased 35%	300 mg daily	Rifabutin AUC decreased 17%; Cmin decreased 24%; 25-O-desacetylrifabutin AUC decreased 17%; Cmax decreased 15%; Cmin decreased 22%	Administer rifabutin 300 mg once daily with etravirine. If etravirine and a protease inhibitor are used together, do not coadminister with rifabutin.
Etravirine MVC 519	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc		No significant change	300 mg BID	Maraviroc AUC decreased 53%; Cmax decreased 60%; Cmin decreased 39%	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Etravirine MVC 518	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increased maraviroc effects		150 mg BID	Maraviroc AUC increased 3.10 fold; Cmax increased 1.76 fold; Cmin increased 5.27 fold	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Etravirine MVC 517	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increased maraviroc effects	No significant change on etravirine, darunavir or ritonavir pharmacokinetics	300 mg BID	Maraviroc AUC increased 210%; Cmax increased 77%; Cmin increased 430%	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Etravirine MVC 516	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Decreased maraviroc effects		300 mg BID	Maraviroc AUC decreased 53%; Cmax decreased 60%; Cmin decreased 39%	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Etravirine Daclatasvir 515	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Potential loss of anti-HCV efficacy	Not studied	120 mg daily	AUC increased 37% and Cmin decreased 17%.	Increase daclatasvir dose to 90 mg daily.
Etravirine Atorvastatin 514	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atorvastatin	Decreased atorvastatin effects	No significant change	40 mg daily	Atorvastatin AUC decreased 37% 2-hydroxyatorvastatin AUC increased 27%; Cmax increased 76%	Consider low dose atorvastatin and titrate to effect; monitor for myopathy
Etravirine RTV 513	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of etravirine	Significant decrease in etravirine concentration and loss of theraputic effect		600 mg BID
Efavirenz ETR 448	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Decreased etravirine and efavirenz effects			Etravirine AUC decreased 41%	Use alternative agents
Doravirine ETR 354	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Potential decrease in antiretroviral efficacy				Do not coadminister. Use alternative agents.
Cabotegravir ETR 332	Green: Administer standard doses	Administer standard doses		Cmax increased 4%, AUC increased 1%	200 mg once daily	Not studied
Raltegravir ETR 309	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 10%; Cmin decreased 34%	200 mg BID	Not reported
Raltegravir ETR 299	Green: Administer standard doses	Administer standard doses		Not reported	200 mg	Etravirine AUC increased 10%, Cmin increased 17%
Dolutegravir ETR 123	Red: Avoid combination	Do not coadminister: Reduced levels of dolutegravir	Potential decrease in antiretroviral efficacy	Cmax decreased 52%, AUC decreased 71%, Cmin decreased 88%	200 mg once daily	Not studied	Contraindicated. Use in combination with ATV / r or DRV / r
Dolutegravir ETR + DRV/r 106	Green: Administer standard doses	Administer standard doses		Cmax decreased 12%, AUC decreased 25%, Cmin decreased 37%	200 mg + 600 / 100 mg BID	Not studied
Maraviroc ETR 38	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy	Maraviroc AUC decreased 53%; Cmin decreased 39%	200 mg BID	Not reported	Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Fostemsavir ETR 5	Green: Administer standard doses	Administer standard doses		Temsavir Cmax decreased 48%, AUC decreased 50%, Cmin decreased 48%	200 mg BID	Etravirine Cmax increased 11%, AUC increased 11%, Cmin increased 14%
Etravirine

Subscribe to Etravirine